Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00996164 · ClinicalTrials.gov registry record · Phase 3
Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder
A Phase 3 study, sponsored by Sprout Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,090
- Enrollment target
NCT00996164 is a Phase 3 study that has completed, run by Sprout Pharmaceuticals. The registered enrollment target is 1,090 participants.
The verdict
NCT00996164, a Phase 3 study, has completed, sponsored by Sprout Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,090 participants
- Enrollment target
Study Summary
The object of this trial is to assess the safety and efficacy of a 24 week course of flibanserin for the treatment of hypoactive sexual desire disorder in premenopausal women.
Interventions
- DRUG Placebo
- DRUG Flibanserin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,090 participants |
| Start Date | 2009-10 |
| Est. Completion | 2011-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00996164
The ClinicalTrials.gov registry entry for NCT00996164 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,090 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sprout Pharmaceuticals, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00996164 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00996164 about?
NCT00996164 is a clinical study titled "Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder". The object of this trial is to assess the safety and efficacy of a 24 week course of flibanserin for the treatment of hypoactive sexual desire disorder in premenopausal women.
What is the current status of trial NCT00996164?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,090 participants. The study started on 2009-10. Estimated completion is 2011-02.
What interventions are being tested in trial NCT00996164?
The interventions under investigation include: Placebo (DRUG), Flibanserin (DRUG).
Who is sponsoring clinical trial NCT00996164?
This trial is sponsored by Sprout Pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.